江西同和药业股份有限公司投资者关系活动记录表 | 证券简称:同和药业 | 证券代码:300636 编号:2023007 | | --- | --- | | | □特定对象调研 □分析师会议 | | | □媒体采访 业绩说明会 | | 投资者关系活动类型 | □新闻发布会 □路演活动 | | | □现场参观 □其他( ) | | 参与单位名称及人员姓名 | 通过深交所互动易平台（http://irm.cninfo.com.cn）"云 | | | 访谈"参与同和药业2022年度网上业绩说明会的投资者。 | | 时间 | 2023年5月17日15:00-16:00 | | 地点 | 公司会议室 | | 公司接待人员姓名 | 公司董事长、总经理庞正伟先生，独立董事彭昕先生，副 | | | 总经理兼董事会秘书周志承先生，财务负责人胡锦桥先生， | | | 保荐代表人刘海燕女士。 1、问：请问公司二厂区建设进度如何？ | | | 答：二厂区一期工程4个车间均已处于试生产阶段。二厂区 一期装置完成试生产后，将使替格瑞洛、维格列汀、阿齐 | | | 沙坦、米拉贝隆、阿哌沙班、依度沙班、富马酸伏诺拉生、 | | | 阿戈美拉 ...

证券代码：300636 证券简称：同和药业 公告编号：2023-034 江西同和药业股份有限公司 关于参加江西辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，江西同和药业股份有限公司 （以下简称"公司"）将参加由江西证监局、江西省上市公司协会与 深圳市全景网络有限公司联合举办的 "2023年江西辖区上市公司投 资者集体接待日活动",现将相关事项公告如下: 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站(https://rs.p5w.net)，或关注微信公众号：全景财经，或下载 全景路演APP，参与本次互动交流，活动时间为2023年5月19日（周五） 15:30-17:00。届时公司高管将在线就公司2022年度业绩、公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等投资者关 心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 江西同和药业股份有限公司董事会 二〇二三年五月十五日 1/ 1 ...

证券代码：300636 证券简称：同和药业 公告编号：2023-032 江西同和药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 江西同和药业股份有限公司（以下简称"公司"）已于2023年4 月24日在巨潮资讯网（www.cninfo.com.cn）上披露了《2022年年度 报告》。 为使投资者更全面地了解公司2022年年度报告的内容，公司定于 2023年5月17日（星期三）下午15:00-16:00举行2022年度网上业绩说 明会，本次年度业绩说明会将通过深圳证券交易所提供的"互动易" 平台举行，投资者可登录"互动易"网站（http://irm.cninfo.com.cn） 进入"云访谈"栏目参与本次年度业绩说明会。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 江西同和药业股份有限公司董事会 二〇二三年五月九日 1/ 1 出席本次年度业绩说明会的人员有：公司董事长、总经理庞正伟 先生，独立董事彭昕先生，副总经理兼董事会秘书周志承先生，财务 负责人胡锦桥先生，保荐代表人刘海燕女士等。 为充分尊重投资者、提升交流的针对性，现就公司2 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 220,746,478.69, representing a 22.79% increase compared to CNY 179,771,415.86 in the same period last year[5] - Net profit attributable to shareholders was CNY 33,096,474.74, up 23.36% from CNY 26,828,215.64 year-on-year[5] - The total operating revenue for the first quarter of 2023 was CNY 220,746,478.69, an increase of 22.8% compared to CNY 179,771,415.86 in the same period last year[23] - The net profit attributable to the parent company for the first quarter of 2023 was CNY 33,096,474.74, compared to CNY 26,828,215.64 in the previous year, representing a growth of 23.4%[24] - The total comprehensive income for the first quarter of 2023 was CNY 33,096,474.74, an increase from CNY 26,828,215.64 in the same period last year, representing a growth of approximately 23.5%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 11.59% to CNY 85,264,632.48 from CNY 96,438,592.52 in the previous year[10] - The company's cash and cash equivalents decreased by 40.15% to CNY 84,960,709.82 from CNY 141,963,915.05 at the beginning of the period[7] - The net cash flow from financing activities increased significantly by 260.43% to CNY 79,153,361.13 from a negative CNY 49,338,103.33 in the previous year[11] - Net cash flow from operating activities was CNY 85,264,632.48, down from CNY 96,438,592.52 in the previous year, indicating a decrease of approximately 11.1%[28] - The company reported a decrease in cash and cash equivalents by CNY 47,370,255.23, compared to a decrease of CNY 81,640,864.77 in the previous year[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,333,114,239.79, a 3.29% increase from CNY 2,258,855,478.13 at the end of the previous year[5] - The total liabilities increased to CNY 972,001,271.81 from CNY 939,186,880.03, indicating a rise of 3.5%[22] - Accounts receivable increased to CNY 117,611,560.19 from CNY 87,829,525.65, marking a growth of 33.9%[21] - Inventory decreased to CNY 467,125,058.50 from CNY 497,358,472.51, a reduction of 6.1%[21] Research and Development - Research and development expenses increased by 67.09% to CNY 19,210,151.13 compared to CNY 11,496,727.71 in the same period last year[9] - The company's R&D expenses for the first quarter of 2023 were CNY 19,210,151.13, up from CNY 11,496,727.71, reflecting a significant increase of 67.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,625[13] - The largest shareholder, Mr. Pang Zhengwei, holds 18.85% of shares, totaling 66,009,954 shares, with 15,750,000 shares pledged[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 15.85% of shares, totaling 55,511,352 shares[13] - The company’s major shareholders, including Mr. Pang and Mr. Liang, are considered acting in concert, jointly controlling the company[14] Capital Projects and Investments - The company has completed the first phase of its new plant project, which includes four workshops that are now in trial production[17] - The company is expanding its second plant with new construction and renovation projects, which commenced in July 2022[17] - The company has completed the application for a specific issuance of A-shares, which has been approved by the Shenzhen Stock Exchange and the China Securities Regulatory Commission[18] Stock and Incentives - The total number of restricted shares at the beginning of the period was 60,606,349, with 77,813 shares released during the period[16] - The company has a stock incentive plan with a total of 5,362,650 shares subject to restrictions[16] - The company has a total of 8,800,000 shares held by Guotai Junan's flexible allocation mixed fund[14] - The company has a total of 3,000,000 shares held by Agricultural Bank of China’s innovative growth mixed fund[14] Operating Costs - The total operating costs for the first quarter of 2023 were CNY 178,963,287.50, up from CNY 149,238,774.57, reflecting a year-over-year increase of 19.9%[24] - The cash inflow from sales of goods and services was CNY 176,923,633.02, slightly down from CNY 176,974,887.71 in the previous year, showing a marginal decline of about 0.03%[28] - The total cash outflow from operating activities was CNY 107,476,010.99, which increased from CNY 102,135,796.85 in the previous year, indicating a rise of approximately 5.3%[28] Other Information - The company did not report any new product launches or technological advancements during this quarter[29]

Financial Performance - The company's operating revenue for 2022 was CNY 719,908,426.87, representing a 21.58% increase compared to CNY 592,126,648.93 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 100,667,359.97, up 24.10% from CNY 81,119,813.17 in 2021[24]. - The cash flow from operating activities increased by 49.23% to CNY 195,996,737.04 in 2022, compared to CNY 131,338,816.17 in 2021[24]. - The total assets at the end of 2022 reached CNY 2,258,855,478.13, an 18.47% increase from CNY 1,906,727,705.65 at the end of 2021[24]. - The net assets attributable to shareholders increased by 48.59% to CNY 1,319,668,598.10 at the end of 2022, compared to CNY 888,112,993.37 at the end of 2021[24]. - The basic earnings per share for 2022 were CNY 0.3084, a 17.40% increase from CNY 0.2627 in 2021[24]. - The company reported a total of CNY 3,271,050.26 in non-recurring gains and losses for 2022, compared to CNY 1,929,871.51 in 2021[30]. - The company achieved a sales revenue of 719.91 million yuan, a year-on-year increase of 21.58%[67]. - The external sales reached 583.91 million yuan, with a growth of 26.79% compared to the previous year[67]. - The net profit for the period was 100.67 million yuan, representing a 24.10% increase from the previous year[67]. - The company reported a total revenue of 1.5 billion for the year 2022, representing a year-on-year growth of 15%[134]. - The company reported a total revenue of 1,644 million in 2022, with a year-on-year increase of 4.823%[159]. - The net profit for the year was 74.21 million, reflecting a growth of 25.04% compared to the previous year[159]. Research and Development - The average R&D investment over the past three years has been 7.74% of sales, indicating a strong focus on innovation and technology development[39]. - The company has established several technology innovation platforms, including the Jiangxi Provincial Engineering Research Center for Specialty Raw Materials, enhancing its R&D capabilities[39]. - The company has completed bioequivalence (BE) for 13 downstream products, including drugs like Venlafaxine and Celecoxib[45]. - The R&D investment amounted to 60.91 million yuan, accounting for 8.46% of the current operating revenue[67]. - The company has a research and development team of over 400 personnel, ensuring efficient selection and rapid market introduction of products with broad market prospects[57]. - The R&D department has successfully filed for 12 new patents, with 8 already granted, indicating a strong focus on innovation[168]. - The company is investing 50 million RMB in new technology to improve production efficiency, targeting a 15% reduction in operational costs[168]. - The company plans to increase R&D investment to improve innovation capabilities and strengthen the CDMO team's capacity for new drug projects[123]. Market Expansion and Strategy - The company is actively pursuing market expansion and new product development to enhance its competitive position in the pharmaceutical sector[4]. - The company has seen a significant increase in demand for its products due to the rising health awareness among the Chinese population[34]. - The company is gradually expanding its contract processing services for original drug manufacturers, in addition to supplying raw materials for generic drug companies[34]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[129]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[127]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million CNY earmarked for potential targets[127]. - The company aims to strengthen brand building and contract manufacturing while focusing on the chemical pharmaceutical industry to enhance its market position[111]. - The company plans to enter two new international markets by the end of 2023[137]. Compliance and Risk Management - The company faces risks related to national policies and industry competition due to ongoing healthcare reforms and regulatory changes[3]. - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company has not experienced any major safety incidents to date, but acknowledges potential risks associated with handling hazardous materials in production[5]. - The company’s product quality is subject to high standards, and any quality issues could adversely affect its reputation and operational performance[6]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finance, with a complete and independent operational system[153]. Employee and Management - The total number of employees at the end of the reporting period is 1,280, with 1,256 from the parent company and 24 from major subsidiaries[181]. - The company has implemented an employee stock incentive plan, with a total of 30.72 million shares allocated for this purpose[159]. - The company has a comprehensive compensation policy that includes competitive salaries, benefits, and performance-based bonuses to motivate employees[182]. - The company aims to enhance its training management system and collaborate with external training institutions to develop employees' potential and management talent[184]. - The company has established a performance evaluation system that links assessment results to compensation, promoting a performance-oriented culture[182]. Environmental Commitment - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company's wastewater treatment capacity is 1,500 tons/day and air treatment capacity is 30,000 cubic meters/hour at one facility, showcasing its commitment to environmental standards[38]. - The company has a strong production capacity with over 600 reaction vessels and a total volume exceeding 3 million liters, positioning it competitively in the global market[66]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[168]. Shareholder Engagement - The company emphasizes the importance of accurate and timely information disclosure, with the chairman as the primary responsible person for information disclosure[150]. - The company has established various channels for investor communication, including dedicated phone lines and email[150]. - The participation rate of investors in the 2022 first extraordinary general meeting was 46.71%[156]. - The company respects and protects the legitimate rights and interests of stakeholders, emphasizing social responsibility and communication[152].